January is Glaucoma Awareness Month, a time dedicated to increasing awareness about glaucoma, a condition that can result in vision loss if not identified early. It is estimated that by 2040, approximately 112 million individuals worldwide will be affected by this condition. Patients who have received a glaucoma diagnosis, as well as those at risk of developing it, can benefit from adhering to the recommendations.
This Guidelines Side-By-Side offers a comprehensive comparison of the current clinical practice guidelines from the American Academy of Ophthalmology (AAO) and the American Optometric Association (AOA). By analyzing these recommendations, the goal of this article is to provide healthcare providers with valuable insights and best practices for assessing and treating POAG. This evidence-based approach aims to improve health outcomes for individuals affected by this condition.
Titles of Comparison:
| Titles | Primary Open-Angle Glaucoma Preferred Practice Pattern® | Care of the Patient with Primary Open-Angle Glaucoma |
|---|---|---|
| Society | American Academy of Ophthalmology (AAO) | American Optometric Association (AOA) |
| Publication Date | November 11, 2020 | October 28, 2024 |
| Objective | To provide evidence-based guidance for ophthalmologists on the diagnosis, treatment, and management of primary open-angle glaucoma | AOA focuses on the role of optometrists in managing POAG, with emphasis on detection, referral, and patient education. |
| Target Population | Aimed at ophthalmologists and other healthcare professionals involved in the management of POAG | Aimed at optometrists and allied health professionals providing eye care |
| Methodology | The Preferred Practice Pattern® guidelines are based on the best available scientific data as interpreted by panels of knowledgeable health professionals. In some instances, such as when results of carefully conducted clinical trials are available, the data are particularly persuasive and provide clear guidance. In other instances, the panels have to rely on their collective judgment and evaluation of available evidence. | “Clinical practice guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of the evidence and an assessment of the benefits and harms of alternative care options.” Based on the IOM/NASEM reports, the AOA Evidence-based Optometry (EBO) Committee developed a 14-stepprocess to meet the new evidence-based recommendations for trustworthy guidelines. |
| Graded Strength of Recommendations | Yes | Yes |
| Graded Level of Evidence | Yes | Yes |
| Systematic Review Conducted | Yes | Yes |
| Literature Review Conducted | Yes | Yes |
| COIs & Funding Source(s) Disclosed | Yes | Yes |
| Full-text | Primary Open-Angle Glaucoma Preferred Practice Pattern® | Care of the Patient with Primary Open-Angle Glaucoma |
| Summary | Summary | Summary |
Comparison of Key Points
| Therapy/Medication | Primary Open-Angle Glaucoma Preferred Practice Pattern® (PPP) | Care of the Patient with Primary Open-Angle Glaucoma |
|---|---|---|
| First-Line Medications | Prostaglandin analogs (e.g., latanoprost, travoprost, bimatoprost) due to efficacy, once-daily dosing, and favorable side-effect profile. | Prostaglandin analogs (e.g., latanoprost, travoprost, bimatoprost) as first-line treatment. Prostaglandin analogs (PGAs) have been found to provide the best IOP-lowering among all the monotherapy topical drugs. |
| Beta-blockers (e.g., timolol) used, though less common due to systemic side effects. | Beta-blockers (e.g., timolol) as a first-line option but with caution in patients with comorbidities. | |
| Alpha agonists (e.g., brimonidine) sometimes used as first-line therapy or adjunctive treatment. | Alpha agonists (e.g., brimonidine) considered for first-line or adjunctive therapy. | |
| Second-Line Medications | Carbonic anhydrase inhibitors (e.g., dorzolamide, brinzolamide) are commonly used as adjuncts when IOP is not sufficiently controlled. | Carbonic anhydrase inhibitors (e.g., dorzolamide, brinzolamide) for adjunctive therapy. |
| Rho kinase inhibitors (e.g., netarsudil) are a second-line or adjunctive therapy in certain cases. | Rho kinase inhibitors (e.g., netarsudil) are mentioned as an option for second-line therapy. | |
| Combination Medications | Combination eye drops (e.g., dorzolamide-timolol) are encouraged to improve adherence and IOP control. | Combination eye drops (e.g., dorzolamide-timolol, brimonidine-timolol) recommended to improve adherence. |
| Laser Therapies | Selective laser trabeculoplasty (SLT) is often a first-line treatment, particularly for patients who are not candidates for medications. | Selective laser trabeculoplasty (SLT) as a first-line or adjunctive treatment, especially for non-compliant patients. |
| Argon laser trabeculoplasty (ALT) may be used as an alternative, though less commonly used today than SLT. | Laser peripheral iridotomy is discussed primarily for angle-closure but can be relevant for secondary POAG. | |
| Surgical Interventions | Trabeculectomy and tube shunt surgery are considered for patients with inadequate IOP control on medications or laser therapy. | Trabeculectomy and tube shunt surgery reserved for patients with uncontrolled IOP despite other therapies. |
| Minimally invasive glaucoma surgery (MIGS) is an emerging option for suitable patients. Although less effective in lowering IOP than trabeculectomy and aqueous shunt surgery, MIGS appears to have a more favorable safety profile in the short term. | Minimally invasive glaucoma surgery (MIGS) techniques are highlighted for cases with moderate glaucoma. Overall, while MIGS as a class have some advantages, there are also some individual device and class disadvantages such as insufficient IOP reduction and complications. | |
| Treatment Considerations | Emphasizes individualized therapy based on patient factors like IOP, disease severity, and side-effect profiles. | Focuses on the need to tailor treatment based on the patient's needs and preferences, as well as disease progression. |
| Treatment should be escalated as necessary, with close monitoring of IOP and optic nerve health. | Regular monitoring of IOP and visual fields is emphasized, with therapy adjusted based on response. |
Similarities:
- Both guidelines emphasize prostaglandin analogs as the first-line therapy.
- Both agree on the use of SLT as a first-line or adjunctive therapy for reducing IOP.
- Beta-blockers and alpha agonists are second-line options in both guidelines, with attention to side effects and patient comorbidities.
- Carbonic anhydrase inhibitors and rho kinase inhibitors are considered second-line or adjunctive options in both.
- Surgical options (trabeculectomy, tube shunts, MIGS) are discussed in both guidelines for cases with poor IOP control despite medications and laser therapies.
Differences:
- Target Audience: AAO’s guidelines are aimed at ophthalmologists and those directly involved in clinical management, while AOA’s guidelines target optometrists and focus on detection and patient management in collaboration with ophthalmologists.
- Management Scope: AAO provides in-depth guidance on medical, laser, and surgical treatments for POAG, whereas AOA focuses more on early detection, monitoring, and the role of optometrists in referring patients to ophthalmologists.
Both the AAO and the AOA developed evidence-based guidelines that stress the importance of early detection and effective management of POAG. However, these guidelines are tailored to different audiences. The AAO's guidelines offer detailed recommendations for ophthalmologists, covering medical, laser, and surgical management strategies for POAG. On the other hand, the AOA's guidelines focus on the role of optometrists in detecting, monitoring, and referring patients to ophthalmologists for advanced treatment when necessary.
Both organizations emphasize the importance of collaboration between eye care providers to ensure the best possible outcomes for patients. The AAO's 2020 guidelines provide a comprehensive clinical framework, while the AOA's 2024 update serves as a practical tool for optometrists in primary care settings. Together, these guidelines highlight the multi-disciplinary approach needed to effectively manage this chronic condition.
Make sure to sign up for guideline alerts on guidelinecentral.com to stay up to date on all future side-by-side blogs and let us know if there is a topic you’d like to see compared on our next article!
Copyright © 2025 Guideline Central, All Rights Reserved.